Furthermore, PARP inhibitors may increase tumor immunogenicity via immunogenic cell death and expansion of the neoantigen repertoire, cGAS-STING pathway activation, upregulation of PD-L1 expression, and immunomodulation of the tumor microenvironment to reflect a TH1 immune response [25,26,27,28,29]. The gene discussed is STING1; the disease is neoplasm.